JP6173911B2 - 抗体誘導体 - Google Patents

抗体誘導体 Download PDF

Info

Publication number
JP6173911B2
JP6173911B2 JP2013527629A JP2013527629A JP6173911B2 JP 6173911 B2 JP6173911 B2 JP 6173911B2 JP 2013527629 A JP2013527629 A JP 2013527629A JP 2013527629 A JP2013527629 A JP 2013527629A JP 6173911 B2 JP6173911 B2 JP 6173911B2
Authority
JP
Japan
Prior art keywords
seq
antibody
sequence
antigen
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013527629A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013545438A (ja
JP2013545438A5 (https=
Inventor
グラブステイン ケンネトフ
グラブステイン ケンネトフ
ブラドイ ウイルリアム
ブラドイ ウイルリアム
キング ゴルドン
キング ゴルドン
ウインブラデ ナイルン ナタリエ
ウインブラデ ナイルン ナタリエ
ダビド シャネベクク クルト
ダビド シャネベクク クルト
ヘフフネル スラグレ パウル
ヘフフネル スラグレ パウル
クフリストプヘル トホルントン ケンネトフ
クフリストプヘル トホルントン ケンネトフ
ペテル バンブルント ミチャエル
ペテル バンブルント ミチャエル
ワング アンドレア
ワング アンドレア
クウ ヘンギュ
クウ ヘンギュ
Original Assignee
メディミューン リミテド
メディミューン リミテド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディミューン リミテド, メディミューン リミテド filed Critical メディミューン リミテド
Publication of JP2013545438A publication Critical patent/JP2013545438A/ja
Publication of JP2013545438A5 publication Critical patent/JP2013545438A5/ja
Application granted granted Critical
Publication of JP6173911B2 publication Critical patent/JP6173911B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2013527629A 2010-09-10 2011-09-09 抗体誘導体 Expired - Fee Related JP6173911B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38178910P 2010-09-10 2010-09-10
US61/381,789 2010-09-10
PCT/EP2011/065697 WO2012032181A2 (en) 2010-09-10 2011-09-09 Novel antibody derivatives

Publications (3)

Publication Number Publication Date
JP2013545438A JP2013545438A (ja) 2013-12-26
JP2013545438A5 JP2013545438A5 (https=) 2014-10-23
JP6173911B2 true JP6173911B2 (ja) 2017-08-09

Family

ID=44583080

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013527629A Expired - Fee Related JP6173911B2 (ja) 2010-09-10 2011-09-09 抗体誘導体

Country Status (5)

Country Link
US (2) US20140127209A1 (https=)
EP (1) EP2640745B1 (https=)
JP (1) JP6173911B2 (https=)
CN (1) CN103261222B (https=)
WO (1) WO2012032181A2 (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
PE20141162A1 (es) 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
TWI812066B (zh) 2010-11-30 2023-08-11 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
CN103796667A (zh) 2011-06-22 2014-05-14 艾普莱斯制药公司 用补体抑制剂治疗慢性障碍的方法
MX343324B (es) 2011-07-06 2016-11-01 Nestec Sa Ensayos para detectar auto anticuerpos neutralizadores de la terapia biologica con tnf alpha.
EP2583979B1 (en) 2011-10-19 2015-12-16 Effimune Methods to prepare antibodies directed against p19 subunit of human IL-23
EP4039275A1 (en) 2012-05-03 2022-08-10 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
PL2859017T3 (pl) 2012-06-08 2019-07-31 Sutro Biopharma, Inc. Przeciwciała zawierające swoiste dla miejsca, niewystępujące naturalnie reszty aminokwasowe, sposoby ich wytwarzania i sposoby ich zastosowania
WO2014004639A1 (en) 2012-06-26 2014-01-03 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
EP3597747B1 (en) 2012-08-24 2023-03-15 Chugai Seiyaku Kabushiki Kaisha Mouse fcgammarii-specific fc antibody
TW202237660A (zh) 2012-08-24 2022-10-01 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
HRP20220455T1 (hr) 2012-08-31 2022-05-27 Sutro Biopharma, Inc. Modificirane aminokiseline koje sadrže azid grupu
SG10201702387YA (en) * 2012-09-24 2017-04-27 Medimmune Ltd Cell lines
BR112015022641B1 (pt) 2013-03-15 2023-02-28 Medimmune Limited Construção de dna e processo de preparação de uma proteína-alvo
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
ES2865473T3 (es) 2013-07-10 2021-10-15 Sutro Biopharma Inc Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
CN105980350B (zh) 2013-08-05 2018-11-27 米迪缪尼有限公司 氨基酸衍生物
EP3143154B1 (en) 2014-05-10 2020-01-29 Sorrento Therapeutics, Inc. Chemically-locked bispecific antibodies
EP3172339A1 (en) 2014-07-24 2017-05-31 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
UA123624C2 (uk) 2014-09-03 2021-05-05 Бьорінґер Інґельхайм Інтернаціональ Ґмбх Сполука, специфічна до іл-23а та фнп-альфа, та її застосування
WO2016088104A2 (en) * 2014-12-05 2016-06-09 Nestec S.A. Indirect homogeneous mobility shift assays for the detection of biologics in patient samples
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
CN107206081A (zh) 2015-02-04 2017-09-26 勃林格殷格翰国际有限公司 治疗炎性疾病的方法
CN114773470A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
US10709839B2 (en) 2015-03-04 2020-07-14 Repro-Med Systems, Inc. Precision variable flow rate infusion system and method
US10906990B2 (en) 2015-08-19 2021-02-02 Riken Antibody with non-natural amino acid introduced therein
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN106924754B (zh) * 2015-12-30 2021-11-09 北京大学 聚氨基酸偶联物
SG11201806419RA (en) 2016-01-27 2018-08-30 Sutro Biopharma Inc Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
TWI693940B (zh) 2016-08-05 2020-05-21 日商中外製藥股份有限公司 Ｉｌ-８相關疾病之治療用或預防用組成物
JP7360324B2 (ja) * 2016-12-23 2023-10-12 ビステラ， インコーポレイテッド 結合ポリペプチドおよびそれを作製する方法
CN110730787B (zh) * 2017-05-09 2023-11-03 辛利斯生物制药有限责任公司 修饰的微囊藻毒素和节球藻毒素
CA3079140A1 (en) * 2017-10-13 2019-04-18 Ursure, Inc. Products and methods for monitoring adherence to nucleoside reverse transcriptase inhibitor therapy
CN110283249A (zh) * 2018-03-19 2019-09-27 江苏莱博德医疗科技有限公司 一种抗白介素6的人ScFv单链抗体
US20190292310A1 (en) * 2018-03-20 2019-09-26 Northeastern University Synthesis of high density molecular dna brushes via organic-phase ring-opening metathesis (co)polymerization
EP3802604A1 (en) 2018-05-31 2021-04-14 Glyconex Inc. Therapeutic antibodies binding to biantennary lewis b and lewis y antigens
AU2019356564A1 (en) * 2018-10-11 2021-04-29 Amgen Inc. Downstream processing of bispecific antibody constructs
US20200405883A1 (en) 2019-06-20 2020-12-31 Baxalta Incorporated Method of treatment with viral-based gene therapy
US12577297B2 (en) 2019-09-09 2026-03-17 Boehringer Ingelheim International Gmbh Anti-IL-23p19 antibody formulations
WO2021202798A1 (en) * 2020-04-02 2021-10-07 The United States Of America As Represented By The Secretary Of The Navy Antigen binding proteins to class 5 etec adhesins
CN113203863B (zh) * 2021-04-28 2022-01-21 北京美联泰科生物技术有限公司 一种适用于白介素-6检测的缓冲液
CN113150122B (zh) * 2021-05-19 2023-03-17 上海儒克生物科技有限公司 高通量全兔源单克隆抗体的制备方法
CA3218489A1 (en) 2021-05-24 2022-12-01 Vir Biotechnology, Inc. Engineered polypeptides
CN115957319B (zh) * 2022-10-14 2023-06-30 北京东方百泰生物科技股份有限公司 一种抗nkg2a单克隆抗体的注射制剂
WO2025010424A1 (en) 2023-07-06 2025-01-09 Vir Biotechnology, Inc. Antibodies against staphylococcus antigens and methods of using the same
PL448731A1 (pl) * 2024-05-31 2025-12-01 Celon Pharma Spółka Akcyjna Przeciwciała bispecyficzne anty–IL-17A i anty-IL-6 oraz ich zastosowanie w terapii, zwłaszcza w leczeniu chorób immunologicznych
CN119023961B (zh) * 2024-08-27 2026-02-03 首都医科大学附属北京朝阳医院 用于检测干眼病生物标志物的试剂及其制备方法和用途
CN120329434B (zh) * 2025-06-23 2025-10-21 杭州市第一人民医院(西湖大学附属杭州市第一人民医院) 一种mfge8单克隆抗体及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016449A1 (en) 1990-04-16 1991-10-31 The Trustees Of The University Of Pennsylvania Saccharide compositions, methods and apparatus for their synthesis
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
GB9915247D0 (en) 1999-07-01 1999-09-01 Amat Limited Improvements relating to tyre degradation
AU4155602A (en) 2000-11-01 2002-06-18 Elusys Therapeutics Inc Method of producing biospecific molecules by protein trans-splicing
US7083970B2 (en) 2001-04-19 2006-08-01 The Scripps Research Institute Methods and compositions for the production of orthogonal tRNA-aminoacyl tRNA synthetase pairs
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP2042196B1 (en) 2001-10-10 2016-07-13 ratiopharm GmbH Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
MXPA05003978A (es) 2002-10-16 2005-06-22 Scripps Research Inst Sintesis de glicoproteinas.
AU2003290330A1 (en) 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US20050287639A1 (en) 2004-05-17 2005-12-29 California Institute Of Technology Methods of incorporating amino acid analogs into proteins
KR101699142B1 (ko) 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
JP2008504356A (ja) * 2004-06-30 2008-02-14 ドマンティス リミテッド 炎症性疾患を治療するための組成物及び方法
TW200708792A (en) 2005-08-24 2007-03-01 Asia Optical Co Inc Retractable lens system and turnover lens-receiving mechanism thereof
EP2444499A3 (en) * 2006-05-02 2012-05-09 Allozyne, Inc. Amino acid substituted molecules
EP2426145B1 (en) * 2007-02-23 2017-01-18 Merck Sharp & Dohme Corp. Engineered anti-il-23p19 antibodies
JP5337055B2 (ja) * 2007-02-28 2013-11-06 メルク・シャープ・アンド・ドーム・コーポレーション 免疫性障害の処置のための組合せ治療
US8188235B2 (en) * 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
US20110158992A1 (en) * 2008-08-27 2011-06-30 Schering Corporation Engineered Anti-IL-23R Antibodies
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010062896A1 (en) * 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
CN104119438A (zh) * 2009-01-29 2014-10-29 米迪缪尼有限公司 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用

Also Published As

Publication number Publication date
EP2640745B1 (en) 2018-11-07
JP2013545438A (ja) 2013-12-26
WO2012032181A9 (en) 2013-06-13
WO2012032181A3 (en) 2012-05-24
CN103261222B (zh) 2017-07-28
CN103261222A (zh) 2013-08-21
US20140127209A1 (en) 2014-05-08
WO2012032181A2 (en) 2012-03-15
EP2640745A2 (en) 2013-09-25
US20160194391A1 (en) 2016-07-07
US10202447B2 (en) 2019-02-12

Similar Documents

Publication Publication Date Title
JP6173911B2 (ja) 抗体誘導体
US20250101074A1 (en) Il-17a-binding polypeptides
TWI801862B (zh) 抗ｔｉｇｉｔ的抗體、其製備方法和應用
KR20180089514A (ko) Tnf-알파, il-17a 및 il-17f에 대해 특이성을 갖는 다중특이적 항체 분자
JP7818828B2 (ja) 特異的結合分子
US20250019452A1 (en) Humanized anti-il-1r3 antibody and methods of use
IL323375A (en) Antibody that specifically binds to claudin 18.2 and method for its preparation and application
JP6137169B2 (ja) 新規抗ヒトｉｌ−２３受容体抗体
WO2022247826A1 (zh) 靶向pd-l1和cd73的特异性结合蛋白
CN120058933B (zh) 抗肿瘤坏死因子样配体1a的抗体及其用途
WO2026085874A1 (zh) Tl1a结合分子及其应用
CN105001331B (zh) 一种vegf单克隆抗体及其应用
HK40033147B (zh) 抗tigit的抗体、其制备方法和应用
HK1238661A1 (en) Il-17a-binding polypeptides
HK1238661B (en) Il-17a-binding polypeptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160719

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170606

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170705

R150 Certificate of patent or registration of utility model

Ref document number: 6173911

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees